Climate Change Data

博晟生醫股份有限公司 BioGend Therapeutics Co., Ltd.

Climate Impact & Sustainability Data (2023)

Reporting Period: 2023

Environmental Metrics

Social Achievements

  • Implemented employee work rules to protect employee rights and interests; maintained smooth communication channels between employees and supervisors; provided employee health checkups, regular education and training, dinner parties and year-end bonuses; contributed 6% of salary to employee's personal pension accounts.

Governance Achievements

  • Established an audit committee and a remuneration committee; implemented a director selection procedure; formulated a Board of Directors Performance Evaluation Methods; purchased director's liability insurance; formulated an Integrity Management Code and Integrity Management Operation Procedures and Behavior Guidelines; established a whistleblowing system.

Climate Goals & Targets

Long-term Goals:
  • Strengthen research and development capabilities; cultivate domestic medical device development talents; increase employment opportunities in the domestic medical device industry.
Medium-term Goals:
  • Evaluate and expand product application areas; evaluate and develop orthopedic medical device products with market potential.
Short-term Goals:
  • Complete BiG-001 Phase I/II clinical trials; obtain clinical trial results; discuss cooperation and licensing matters with international major manufacturers; change from dealers to direct sales for BiG-009; accelerate second-generation product development for BiG-009.

Environmental Challenges

  • R&D risk (uncertain success rate in each stage of development); capital risk (long development time and high costs); market competition risk (emergence of new technologies and products).
Mitigation Strategies
  • Applied for multi-country and multi-center clinical trials; signed joint development contracts with partners from various countries; cooperated with professional CRO companies and regulatory consulting companies; optimized products and expanded product lines; effectively used government policies; carried out various cash capital increases; listed on the OTC; grasped the latest medical and industrial trends; planned patent applications.

Supply Chain Management

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: IFRS

Third-party Assurance: Price Waterhouse Cooper, Taiwan

Awards & Recognition

  • Taiwan Excellence Award
  • National Pharmaceutical Technology Research and Development Award